Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies
نویسندگان
چکیده
منابع مشابه
Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis
Background: Treatment of cancers with programmed cell death protein 1 (PD-1) pathway inhibitors can lead to immune-related adverse events (irAEs), which could be serious and even fetal. Therefore, clinicians should be aware of the characteristics of irAEs associated with the use of such drugs. Methods: The MEDLINE, EMBASE, and Cochrane databases were searched to find potential studies using the...
متن کاملANTI CARDIOLIPIN ANTIBODIES IN PATIENTS WITH ISCHEMIC EVENTS
To determine the presence of anticardiolipin (aCL) antibodies in patients with ischemic events, we designed a case-control study. We studied 33 patients with unstable angina, 33 male patients with myocardial infarction and 34 control subjects with no evidence of ischemic heart disease. Plasma samples were assessed for IgG anticardiolipin antibodies by enzyme-linked immunosorbent assay (ELI...
متن کاملAdverse cardiac events to monoclonal antibodies used for cancer therapy
Monoclonal antibodies are currently used in the treatment of neoplastic, hematological, or inflammatory diseases, a practice that is occasionally associated with a variety of systemic and cutaneous adverse events. Cardiac adverse events include cardiomyopathy, ventricular dysfunction, arrhythmias, arrests, and acute coronary syndromes, such as acute myocardial infarction and vasospastic angina ...
متن کاملImmune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis
OBJECTIVE To evaluate rates of serious organ specific immune-related adverse events, general adverse events related to immune activation, and adverse events consistent with musculoskeletal problems for anti-programmed cell death 1 (PD-1) drugs overall and compared with control treatments. DESIGN Systematic review and meta-analysis. DATA SOURCES Medline, Embase, Cochrane Library, Web of Scie...
متن کاملAdverse Events of Monoclonal Antibodies Used for Cancer Therapy
In 1997, the first monoclonal antibody (MoAb), the chimeric anti-CD20 molecule rituximab, was approved by the US Food and Drug administration for use in cancer patients. Since then, the panel of MoAbs that are approved by international regulatory agencies for the treatment of hematopoietic and solid malignancies has continued to expand, currently encompassing a stunning amount of 20 distinct mo...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Neurology
سال: 2019
ISSN: 0028-3878,1526-632X
DOI: 10.1212/wnl.0000000000007235